This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Zealand Pharma A/S
Drug Names(s): ZP1848, ZP 1848, ZP-1848, Glepaglutide
Description: ZP1848 is a Glucagon-Like Peptide-2 agonist which incorporates Zealand'sproprietary SIP-technology. One of the aims of the SIP-technology (Structure-Inducing Probe technology) is to optimize the therapeutic profile of a broad range of active peptides (e.g., increased efficacy, increased drug stability, and increased persistence in the human body).
Glucagon-like Peptide-2 (GLP-2) is a naturally occurring peptide hormone,secreted by the small intestine. GLP-2 binds to and acts exclusively via the GLP-2 receptor, expressed primarily in the gastrointestinal tract. GLP-2 has beenshown to have numerous beneficial effects in the small intestine. These includestimulation of the growth of the small intestinal lining, enhancement of nutrientdigestion and absorption, and reinforcement of the intestinal barrier function.Moreover, GLP-2 has been shown to decrease inflammation, and to enhanceanimal survival in a broad range of preclinical models of gut injury including,models of Inflammatory Bowel Disease.
Additional information available to subscribers only: